79 results
DEFM14A
APGN
Apexigen Inc
30 Jun 23
Proxy related to merger
4:21pm
will be sought. There can be no assurance, however, that any additional approvals or actions will be obtained.
Accounting Treatment of the Merger (see … as well as the amount of cash that Apexigen will need to reserve for commitments and contingent liabilities.
There can be no assurance that the Merger
425
PYXS
Pyxis Oncology Inc
24 May 23
Business combination disclosure
7:05am
) reasonably designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements … reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and that receipts
8-K
EX-2.1
hvfyabtcvo67 nhm853o
24 May 23
Pyxis Oncology to Acquire Apexigen
7:02am
8-K
tslwjrfhkx6tg
12 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:25pm
424B3
e7d1 jp0i8s7w3
10 Apr 23
Prospectus supplement
4:03pm
424B3
tadjt
10 Apr 23
Prospectus supplement
4:02pm
POS AM
izqqcs324
4 Apr 23
Prospectus update (post-effective amendment)
4:24pm
POS AM
8khp 0qy8o
4 Apr 23
Prospectus update (post-effective amendment)
4:23pm
8-K
EX-99.1
6pilvge0
14 Nov 22
Changes in Registrant's Certifying Accountant
4:07pm
424B3
k9ze7t2
9 Sep 22
Prospectus supplement
4:40pm
424B3
n87j0g
9 Sep 22
Prospectus supplement
4:38pm